Reuters logo
3 months ago
BRIEF-Genentech says U.S. FDA approves Lucentis (ranibizumab injection) for diabetic retinopathy
April 17, 2017 / 5:57 PM / 3 months ago

BRIEF-Genentech says U.S. FDA approves Lucentis (ranibizumab injection) for diabetic retinopathy

1 Min Read

April 17 (Reuters) - Genentech:

* FDA approves Genentech’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States

* FDA approved Lucentis 0.3 mg for monthly treatment of all forms of diabetic retinopathy

* In analysis that supported approval, patients with/without DME in Lucentis group experienced improvements in severity of their retinopathy Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below